NIH-funded research R01 grant

How oxidative stress may cause Fuchs endothelial corneal dystrophy

Official title: Role of Oxidative Stress in Pathogenesis of Fuchs Endothelial Corneal Dystrophy

Funded at Schepens Eye Research Institute · NIH-11141733 · Data updated 2026-11-12

This research looks at whether oxidative stress from aging, UV-A light, and smoking harms corneal endothelial cells and leads to Fuchs dystrophy, especially in older women.

More Oxidative Stress research and trials

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionSchepens Eye Research Institute
NIH-funded
Lab location1 site (Boston, United States)
Project startJuly 1, 2010
Project endJuly 31, 2029
Funding year2025
Award (this year)$602,106
NIH project number5R01EY020581-16
Project IDNIH-11141733 on NIH RePORTER

Who could benefit from this research

Could help

People diagnosed with Fuchs endothelial corneal dystrophy—particularly older adults, women, and those with a history of smoking or significant UV exposure—would be most relevant to this research.

Less likely to help

People without FECD or those whose disease is already end-stage and awaiting corneal transplant are unlikely to directly benefit from this mechanistic research in the short term.

What this research studies

Researchers are studying how aging, UV-A exposure, and smoking upset the balance between oxidants and antioxidants in corneal endothelial cells and lead to the cell loss and guttae seen in Fuchs dystrophy. They will use lab models (cells and mice) and molecular tests to examine mitochondrial DNA damage, cell cycle arrest, polyploidy, and abnormal extracellular matrix that cause corneal scarring. The team will probe hormone-related enzymes and receptors (such as AhR and CYP1B1) and changes in melatonin chemistry that may make female eyes more vulnerable. This work builds on earlier findings linking oxidative DNA damage and mitochondrial dysfunction to FECD.

Why it matters

Potential benefit: If successful, the findings could point to new ways to protect corneal endothelial cells or prevent the guttae and scarring that lead to vision loss.

How similar studies have gone: Previous studies, including the investigators' own work, have linked oxidative and mitochondrial DNA damage to FECD, but the proposed AhR/CYP1B1–melatonin pathway and its connection to guttae formation are relatively novel.

Where this research is happening

  • Schepens Eye Research Institute
    Boston, United States
    Active

Researchers

  • Principal investigator: Jurkunas, Ula V. — Schepens Eye Research Institute
  • Study coordinator: Jurkunas, Ula V.

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.